Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Immunomedics awarded four grants from the NIH for development of cancer therapies

Sep. 6, 1999

No Comments

Maxamine combination treatment for AML effective in phase II studies

Sep. 6, 1999

No Comments

FDA requests modifications to Bexxar BLA

Aug. 31, 1999

No Comments

Herceptin approved in Canada for breast cancer therapy

Aug. 30, 1999

No Comments

Berlex acquires marketing rights to Campath

Aug. 25, 1999

No Comments

Chiron files long-term survival data for Proleukin with the FDA

Aug. 23, 1999

No Comments

Clinical trials of SRL-172 in lung cancer are progressing

Aug. 20, 1999

No Comments

Biomira's BLP25 cancer vaccine tested at higher dose and frequency

Aug. 17, 1999

No Comments

CEA-Cide granted orphan drug status for ovarian cancer

Aug. 13, 1999

No Comments

Vaccination with HPV16 peptides in advanced cervical carcinoma

Aug. 6, 1999

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Immuno-oncology
RSS

Immunomedics awarded four grants from the NIH for development of cancer therapies

Maxamine combination treatment for AML effective in phase II studies

FDA requests modifications to Bexxar BLA

Herceptin approved in Canada for breast cancer therapy

Berlex acquires marketing rights to Campath

Chiron files long-term survival data for Proleukin with the FDA

Clinical trials of SRL-172 in lung cancer are progressing

Biomira's BLP25 cancer vaccine tested at higher dose and frequency

CEA-Cide granted orphan drug status for ovarian cancer

Vaccination with HPV16 peptides in advanced cervical carcinoma

Today's news in brief

Today's news in brief

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space

GLP-1 receptor agonists continue their global victory tour

AI drives financings, approvals for APAC med-tech in 2024

Immuno-oncology RSS

Immuno-oncology
RSS